Arcellx (NASDAQ:ACLX) Insider Sells $10,243,230.72 in Stock

February 28, 2026 by InsiderTrades.com

Key Points

Insider sale: Director Rami Elghandour sold 89,916 shares at an average of $113.92 for about $10.24M, cutting his position by ~24.6% to 276,051 shares (worth roughly $31.45M).
Revenue miss: Q results showed EPS of $(1.01) (in line) but revenue of $1.65M versus $13.4M expected, a sizable shortfall that increases near-term execution risk and volatility.
Analyst sentiment: Several firms have moved ACLX toward neutral/hold (UBS, Guggenheim, Stifel), leaving a MarketBeat average rating of "Hold" and an average price target of $111.87, roughly in line with the stock's recent ~$114 level.

Arcellx, Inc. (NASDAQ:ACLX - Get Free Report) insider Rami Elghandour sold 89,916 shares of the company's stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $113.92, for a total value of $10,243,230.72. Following the sale, the insider owned 276,051 shares of the company's stock, valued at $31,447,729.92. This trade represents a 24.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Arcellx Stock Performance

Shares of ACLX opened at $113.79 on Friday. The stock has a market capitalization of $6.58 billion, a P/E ratio of -28.95 and a beta of 0.36. Arcellx, Inc. has a 1 year low of $47.86 and a 1 year high of $114.26. The company's fifty day moving average is $71.81 and its two-hundred day moving average is $76.22.

Institutional Trading of Arcellx

Institutional investors have recently made changes to their positions in the stock. MAI Capital Management acquired a new stake in shares of Arcellx in the third quarter worth $26,000. CWM LLC grew its position in Arcellx by 267.0% in the third quarter. CWM LLC now owns 345 shares of the company's stock valued at $28,000 after acquiring an additional 251 shares in the last quarter. State of Wyoming acquired a new position in shares of Arcellx during the second quarter worth $28,000. Ramirez Asset Management Inc. purchased a new position in shares of Arcellx in the third quarter valued at $41,000. Finally, Abich Financial Wealth Management LLC acquired a new stake in Arcellx during the 3rd quarter valued at $62,000. 96.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ACLX has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Arcellx in a report on Wednesday, January 21st. UBS Group downgraded Arcellx from a "buy" rating to a "neutral" rating and lifted their price target for the company from $100.00 to $115.00 in a research note on Tuesday. Stifel Nicolaus reaffirmed a "hold" rating and set a $115.00 price objective (down from $127.00) on shares of Arcellx in a report on Monday. Leerink Partners reissued a "market perform" rating and issued a $115.00 target price on shares of Arcellx in a report on Tuesday. Finally, Guggenheim lowered shares of Arcellx from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $120.00 to $115.00 in a research report on Wednesday. One analyst has rated the stock with a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $111.87.

Get Our Latest Analysis on ACLX

Arcellx News Summary

Here are the key news stories impacting Arcellx this week:

Neutral Sentiment: Reported short-interest data shows zero shares and a 0.0 days-to-cover figure for late February; this looks like a data or reporting anomaly rather than a meaningful change in market positioning — monitor for corrected filings or confirmations from exchanges.
Neutral Sentiment: HC Wainwright published an FY2030 earnings forecast for Arcellx; long-range model updates can influence valuation assumptions but are less likely to move the stock immediately than near-term operational news. FY2030 Earnings Forecast for Arcellx Issued By HC Wainwright
Neutral Sentiment: Market commentary pieces (example: "Is It Too Late To Consider Arcellx...") are evaluating the recent run-up and valuation; these are background reads that may sway retail interest but do not constitute new company fundamentals. Is It Too Late To Consider Arcellx (ACLX) After Its Recent Share Price Surge?
Negative Sentiment: Insider selling: Director Rami Elghandour sold 89,916 shares at ~$113.92 (≈$10.24M), cutting his stake by ~24.6%. Large insider sales at current levels can weigh on sentiment, especially after a recent price run. SEC Filing
Negative Sentiment: Quarterly results: ACLX reported EPS of ($1.01), matching consensus, but revenue was $1.65M vs. expectations of $13.4M — a sizable revenue shortfall that highlights execution or timing risk and likely increases near-term volatility and downside pressure.
Negative Sentiment: Analyst actions: UBS downgraded the stock, and both Robert W. Baird and Canaccord Genuity moved ACLX to "Hold" — multiple downward analyst moves reduce buy-side momentum and can trigger short-term selling. UBS downgrades Arcellx (ACLX) Cut to Hold at Robert W. Baird Cut to Hold at Canaccord Genuity Group

About Arcellx

(Get Free Report)

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company's proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company's pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.